Why Did Piper Sandler Give Intra-Cellular Therapies Inc (ITCI) Stock Overweight Rating?
Intra-Cellular Therapies Inc (ITCI) stock saw a modest uptick, ending the day at $126.5 which represents a slight increase of $0.30 or 0.24% from the prior close of $126.2. The stock opened at $126.64 and touched a low of $126.
That's changed: Lyons is acknowledged heir apparent at a giant fintech where he'll become CEO by July at the latest.
In a report released today, Arvind Ramnani from Piper Sandler maintained a Hold rating on PayPal Holdings (PYPL – Research Report), with a ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 14.59% ...
Tesla remains the “top buy-and-hold” stock for analysts at Piper Sandler, who massively raised their price target for the ...
Piper Sandler analyst Michael Lavery maintained a Buy rating on PepsiCo (PEP – Research Report) today and set a price target of $171.00. The ...
Piper Sandler Companies operates as an investment bank and institutional securities firm that serves corporations, private equity groups, public entities, non-profit entities, and institutional ...
MarketWatch on MSN3d
Tesla’s ‘Trump bump’ fades as stock falls alongside rest of EV sectorTesla shares TSLA ended the day down 0.6%, after falling as much as 4% intraday, tracking losses in the broader EV space, ...
NEW YORK, January 13, 2025--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of John Kerins as a managing director to the healthcare investment ...
Piper Sandler reiterated an Overweight rating and $670 price target on Meta Platforms (META) after CEO Mark Zuckerberg said in a Facebook post ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback